Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 102 of 6351
-
New hope for advanced breast cancer: trial tests Two-Drug combo
Disease control Recruiting nowThe purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unre…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo pill aims to cut heart deaths in patients with failing kidneys
Disease control Recruiting nowThis is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/da…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New CAR t-cell combo aims to beat leukemia relapse
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, two-arm, non-inferior trial. Patients with r/r B-ALL would be assigned to the CD19 CAR and CD22 CAR T-cell sequential infusion group (Sequential CAR, Arm-1) and the CD19 CAR T-cell infusion bridging to hematopoietic stem cell tr…
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for lung cancer: drug duo takes on standard therapy
Disease control Recruiting nowThe purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Brain tumor trial aims to boost radiation without boosting harm
Disease control Recruiting nowGlioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multic…
Phase 2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could an mRNA vaccine stop kidney cancer from returning?
Disease control OngoingThe primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intism…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a targeted drug combo replace harsh chemo for NPM1 leukemia?
Disease control Recruiting nowThis phase II clinical trial evaluates the efficacy and tolerability of the non-intensive treatment with venetoclax and the hypomethylating agent azacitidine as compared to the standard of care chemotherapy plus gemtuzumab ozogamicin in newly diagnosed NPM1 mutated AML patients f…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?
Disease control Recruiting nowThis is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
Phase 3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThe goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors tha…
Phase 1/2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for stroke patients: clot removal in tiny brain arteries under trial
Disease control Recruiting nowA phase III, randomized, multi-center, investigational, open label clinical trial that will examine whether treatment with endovascular thrombectomy is superior to standard medical therapy alone in patients who suffer a Distal Medium Vessel Occlusion Ischemic Stroke within 12 hou…
Sponsor: Raul Nogueira • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New RSV vaccine shows promise for seniors in large trial
Vaccine CompletedThe purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV. The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-…
Phase 2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
Immune cells from your own tumor could fight cervical cancer
Disease control Recruiting nowThis is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Phase 2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2 negative breast cancer that has spread from where it fi…
Phase 1/2 • Sponsor: Margaret Gatti-Mays • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Virtual companion 'Ida' may ease cancer distress in kids
Symptom relief CompletedThe goal of this clinical trial is to learn if an augmented reality (AR) mobile app-based cognitive behavioral therapy (CBT) program can help children aged 6 to 12 years who are being treated for cancer cope with treatment-related distress and improve their quality of life. The m…
Sponsor: Koç University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
New RSV shot protects thousands of babies from severe illness
Prevention CompletedThe primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters. the secondary objectives are: 1. To estimate the effectiveness of ni…
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
MRNA tech takes on the flu: could new shots outsmart seasonal strains?
Vaccine CompletedThe purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV-…
Phase 1/2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Aug 06, 2026 00:00 UTC
-
Inhaled interferon could be new weapon against severe RSV in young children
Disease control Recruiting nowTo evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.
Phase 3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a blast of cold air save your brain after a heart attack?
Disease control Recruiting nowThe aim of this clinical trial is to study the impact of ultra-early transnasal evaporative cooling after cardiac arrest and subsequent hypothermia at hospital, on survival with complete neurologic recovery, compared to currently recommended normothermia. The study population wil…
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a common steroid tame deadly lung infections in the ICU?
Disease control Recruiting nowDetermine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an international phase III, double-blind, placebo-controlled, rand…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New X-Ray technique could help rectal cancer patients avoid colostomy
Disease control Recruiting nowIndication : Adult patients with intermediate low or mid rectal adenocarcinoma to be treated with total neoadjuvant therapy (TNT) potentially eligible for rectal preservation. Primary objective is to assess efficacy of contact X-ray brachytherapy (CXB) in addition to TNT in orde…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC